Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: JustTradeEm who wrote (88027)	6/2/2003 11:04:19 AM
From: JustTradeEm	Respond to of 208838

Long DNDN @ 6.83, long BRCM @ 24.58 ... JB

To: JustTradeEm who wrote (88027)	6/2/2003 12:23:26 PM
From: JustTradeEm	Respond to of 208838

DNDN from Dow Jones : 12:00 ET DJ Dendreon/Study -3: Three Patients Had PSA Decreases ¨ 02 Jun 12:00 Dendreon said that PSA doubling time is a measure of the rate of change of PSA over time. A change in PSA doubling time can be calculated only for patients who have a rising PSA after therapy. The company said that three patients also had PSA decreases from baseline of 12%, 33% and 64% respectively. The phase 2 trial was sponsored by the National Cancer Institute. The research was conducted at the University of California-San Francisco. The results were presented Monday to the American Society of Clinical Oncology's 2003 annual meeting by Dr. Brian Rini, M.D., of the University of California-San Francisco. -Thomas Derpinghaus; Dow Jones Newswires; 201-938-5400 (END) Dow Jones Newswires 06-02-03 1200ET